Reduced Circulating miR-15b Is Correlated with Phosphate Metabolism in Patients with End-Stage Renal Disease on Maintenance Hemodialysis

Figures & data

Table 1. Baseline clinical data of the subjects.

	ESRD (n = 30)	Healthy controls (n = 20)	p
Age (mean ± SD)	52.17 ± 11.73	49.25 ± 11.25	0.386
Male (%)	73	60	–
Chronic GN, No. (%)	100	–	–
eGFR (mL/min)	8.38 ± 1.97	–	–
Blood pressure
Systolic (mmHg)	144 ± 15.62	125 ± 10	<0.001
Diastolic (mmHg)	87 ± 10.5	84 ± 7	0.273
Hemoglobin (mg/dL)	91 ± 13.61	116 ± 9.5	<0.001
Albumin (g/dL)	3.6 ± 0.6	4.6 ± 0.6	<0.001
CRP (mg/L)	10.89 ± 9.1	1.12 ± 0.48	<0.001
Calcium (mmol/L)	2.26 ± 0.38	2.31 ± 0.29	0.562
Phosphate (mmol/L)	2.1 ± 0.4	1.2 ± 0.19	<0.001

Notes: GN, glomerular nephritis; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein. Values are mean ± SD; data are compared by Student t–test.

Figure 1. Circulating miRNAs in patients with ESRD and healthy controls.

Notes: Expression of miR-15b in plasma obtained from patients with ESRD (n = 30) and healthy controls (n = 20), as determined by RT-qPCR. Plasma miR-15b level was indicated by 2^−ΔΔCT; prehemodialysis (pre-HD) versus healthy controls, p < 0.001; posthemodialysis (post-HD) versus healthy controls, p < 0.001; pre-HD versus post-HD, p > 0.05. *p < 0.001 probability values were calculated by ANOVA test with Tukey posttest.

Figure 2. Correlations between circulating miR-15b and (A) eGFR; (B) hemoglobin; (C) phosphate; (D) CRP; (E) albumin; (F) calcium.